RxDoctor Payments Data

Dana Delaski, NP

Family · Jackson, MSNPI 1467753772

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Incyte Corporation accounts for 91.4% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2022 at $53,254 and has fallen 75.6% since, to $12,976 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$158,131in general payments, 2019–2025

Across 854 payments — averaging $185.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$144K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • AstraZeneca$987
  • Vertex$932
  • Bristol Myers Squibb$766
  • Novartis$560
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$3,3992%
  • Speaking & faculty fees$90,19357%
  • Travel & lodging$46,12329%
  • Food & beverage$18,23712%
  • Education$1790%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation357$144,456
Takeda Pharmaceuticals U.S.A., Inc.22$1,862
AstraZeneca(2 entities)30$987
Vertex1$932
Bristol Myers Squibb30$766
Novartis33$560
Sanofi29$550
Beigene USA, Inc.12$475
Johnson & Johnson(2 entities)26$444
Genentech USA, Inc.17$388
E.r. Squibb & Sons, L.L.C.7$374
Merck17$353
AbbVie17$327
Pharmacosmos Therapeutics Inc.7$298
Rigel Pharmaceuticals, Inc.12$292
Astellas Pharma US Inc13$286
Pfizer15$265
Gilead(2 entities)10$257
Ipsen Biopharmaceuticals, Inc8$231
Janssen Scientific Affairs, LLC2$230
Pharmacyclics LLC, An Abbvie Company5$227
Amgen15$208
Blueprint Medicines Corporation8$204
GSK8$181
Emmaus Medical, Inc.10$177
Karyopharm Therapeutics Inc.9$166
Sanofi-aventis U.S. LLC8$161
Seagen Inc.10$155
Daiichi Sankyo Inc.8$149
Bayer7$147
Adaptive Biotechnologies Corporation6$132
Alnylam Pharmaceuticals Inc.8$128
Puma Biotechnology, Inc.3$116
Immunocore Limited4$108
Stemline Therapeutics Inc.5$104
Pharmaessentia USA Corporation5$104
Taiho Oncology, Inc.4$96
Regeneron Healthcare Solutions, Inc.4$96
EMD Serono, Inc.6$93
Sobi, Inc4$90
Morphosys, US Inc.4$64
Genentech, Inc.1$62
Servier Pharmaceuticals LLC4$57
ADC Therapeutics America, Inc.3$57
Beone Medicines USA, Inc.3$53
Legend Biotech USA Inc.2$48
Novo Nordisk2$46
Jazz Pharmaceuticals Inc.2$44
Acceleron Pharma, Inc.3$41
Sanofi US Services Inc.2$40
AVEO Pharmaceuticals, Inc.2$39
Myovant Sciences Inc.2$37
Array Biopharma Inc2$32
Bard Peripheral Vascular, Inc.2$31
Eisai Inc.2$31
Boehringer Ingelheim2$30
Geron Corporation1$25
Genmab U.S., Inc.1$22
G1 Therapeutics, Inc.1$21
Recordati_rare_diseases_inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,131 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$22,925
Medicare patients
149
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Deferasirox48$153,763
XareltoRivaroxaban33$28,283
EliquisApixaban37$21,360
Morphine Sulfate ErMorphine Sulfate53$1,693
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen98$1,260
Hydroxyurea42$1,253
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen42$1,179
Gabapentin50$760
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$696
Colestipol Hcl13$683
Fentanyl12$657
Acyclovir39$615
Tamsulosin Hcl21$572
Dexamethasone20$348
Prochlorperazine Maleate17$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$444$28,28333 claims
PfizerEliquis$265$21,36037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →